Nutritional Advice El Mondo
Objectives:
What is the efficacy and safety of umifenovir in COVID-19?
Study design:
This review article included 12 studies with 1,052 patients.
Results and conclusions:
The investigators found compared with control group, umifenovir was associated with higher negative rate of PCR on day 14 [RR = 1.27, 95% CI = 1.04 to 1.5].
The results of sensitivity analysis and subgroup analysis were similar to pooled results.
The investigators found, however, compared with control group, umifenovir was not related to nucleus acid negative conversion time [MD = 0.09, 95% CI = -1.48 to 1.65], negative rate on day 7 [RR =1.09, 95% CI = 0.91 to 1.31], incidence of composite endpoint [RR = 1.20, 95% CI = 0.61 to 2.37], rate of fever alleviation on day 7 [RR =1.00, 95% CI= 0.91 to 1.10], rate of cough alleviation on day 7 [RR = 1.00, 95% CI = 0.85 to 1.18] or hospital length of stay (LOS) [MD = 1.34, 95% CI = -2.08 to 4.76].
The results of sensitivity analysis and subgroup analysis were similar to pooled results.
The investigators found, additionally, umifenovir was safe in COVID-19 patients [RR for incidence of adverse events = 1.29, 95% CI = 0.57 to 2.92].
The results of sensitivity analysis and subgroup analysis were similar to pooled results.
The investigators concluded there is no evidence to support the use of umifenovir for improving patient-important outcomes in patients with COVID-19.
Original title:
Efficacy and Safety of Umifenovir for Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis by Huang D, Yu H, […], Liang Z.
Link:
https://pubmed.ncbi.nlm.nih.gov/32617989/
Additional information of El Mondo:
Find more information/studies on coronavirus right here.